Evidence map›Paper›PMID 32375768›Full record

ArticleMolecular cancer2020

Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis.

Xiaofeng Guo, Quanbo Zhou, Dan Su, Yuming Luo, Zhiqiang Fu, Leyi Huang, Zhiguo Li, Decan Jiang, Yao Kong, Zhihua Li and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 1 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 1 synthesis or guideline pooled it, 148 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Circular RNAs and Cancers.Advances in experimental medicine and biology · 2025
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Xiaofeng GuoDepartment of Pancreatobiliary Surgery, Sun Yat-sen Memorial Hospital, 107 Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, 510120, P. R. China.
Quanbo ZhouDepartment of Pancreatobiliary Surgery, Sun Yat-sen Memorial Hospital, 107 Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, 510120, P. R. China.
Dan SuDepartment of Pancreatobiliary Surgery, Sun Yat-sen Memorial Hospital, 107 Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, 510120, P. R. China.
Yuming LuoDepartment of Pancreatobiliary Surgery, Sun Yat-sen Memorial Hospital, 107 Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, 510120, P. R. China.
Zhiqiang FuDepartment of Pancreatobiliary Surgery, Sun Yat-sen Memorial Hospital, 107 Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, 510120, P. R. China.
Leyi HuangDepartment of Pancreatobiliary Surgery, Sun Yat-sen Memorial Hospital, 107 Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, 510120, P. R. China.
Zhiguo LiDepartment of Pancreatobiliary Surgery, Sun Yat-sen Memorial Hospital, 107 Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, 510120, P. R. China.
Decan JiangAffiliated Huadu Hospital, Southern Medical University, 48 Xinhua Road, Huadu District, Guangzhou, Guangdong, 510800, P. R. China.
Yao KongDepartment of Ultrasound, Sun Yat-sen Memorial Hospital, 107 Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, 510120, P. R. China.
Zhihua LiDepartment of Medical Oncology, Sun Yat-sen Memorial Hospital, 107 Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, 510120, P. R. China. lzhdoct@163.com.
Rufu ChenDepartment of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Yuexiu District, Guangzhou, Guangdong, 510080, P.R. China. chenrf63@163.com.
Changhao ChenGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, State Key Laboratory of Oncology in South China, 107 Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, 510120, P. R. China. chenchh53@mail.sysu.edu.cn.
Sun Yat-sen University · CNSun Yat-sen Memorial Hospital · CNGuangdong Academy of Medical Sciences · CNSouthern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccumulating evidence suggests that circular RNAs (circRNAs) are important participants in cancer progression. However, the biological processes and underlying mechanisms of circRNAs in pancreatic ductal adenocarcinoma (PDAC) are unclear.

methodCircRNAs were verified by Sanger sequencing. Colony formation, 5-Ethynyl-2'-deoxyuridine (EdU), and Transwell assays were performed to investigate the effect of circBFAR on the proliferation, invasion, and migration of PDAC cells in vitro. RNA pull-down assays were conducted to verify the binding of circBFAR with microRNA miR-34b-5p.

resultsIn the present study, we identified a novel circRNA (termed as circBFAR, hsa_circ_0009065) that was upregulated in a 208-case cohort of patients with PDAC. The ectopic expression of circBFAR correlated positively with the tumor-node-metastasis (TNM) stage and was related to poorer prognosis of patients with PDAC. Moreover, circBFAR knockdown dramatically inhibited the proliferation and motility of PDAC cells in vitro and their tumor-promoting and metastasis properties in in vivo models. Mechanistically, circBFAR upregulated mesenchymal-epithelial transition factor (MET) expression via sponging miR-34b-5p. Additionally, circBFAR overexpression increased the expression of MET and activated downstream phosphorylation of Akt (Ser 473) and further activated the MET/PI3K/Akt signaling pathway, which ultimately promoted the progression of PDAC cells. Importantly, application of MET inhibitors could significantly attenuate circBFAR-mediated tumorigenesis in vivo.

conclusionsOur findings showed that circBFAR plays an important role in the proliferation and metastasis of PDAC, which might be explored as a potential prognostic marker and therapeutic target for PDAC.

Indexed as

AnimalsApoptosisBiomarkers, TumorCarcinoma, Pancreatic DuctalCell ProliferationGene Expression Regulation, NeoplasticHumansMiceMice, SCIDMicroRNAsPancreatic NeoplasmsPrognosisProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-metRNA, CircularTumor Cells, CulturedAKT1 protein, humanBiomarkers, TumorMET protein, humanMicroRNAsMIRN34 microRNA, humanProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-metRNA, CircularcircBFARMETmiR-34b-5pPancreatic ductal adenocarcinomaPI3K/Akt pathway

Identifiers

PMID32375768
PMCPMC7201986
OpenAlexW3021281398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.